Intech Investment Management LLC Sells 12,125 Shares of Vera Therapeutics, Inc. $VERA

Intech Investment Management LLC cut its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 41.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,414 shares of the company’s stock after selling 12,125 shares during the quarter. Intech Investment Management LLC’s holdings in Vera Therapeutics were worth $506,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of VERA. Virtus Investment Advisers LLC boosted its holdings in Vera Therapeutics by 14.8% during the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock valued at $98,000 after acquiring an additional 539 shares during the period. Invesco Ltd. increased its stake in shares of Vera Therapeutics by 2.0% in the second quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock worth $656,000 after purchasing an additional 550 shares during the period. Ameritas Investment Partners Inc. lifted its position in shares of Vera Therapeutics by 13.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,254 shares of the company’s stock worth $124,000 after purchasing an additional 615 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Vera Therapeutics by 2.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,721 shares of the company’s stock worth $744,000 after purchasing an additional 816 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in Vera Therapeutics by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock valued at $1,188,000 after purchasing an additional 825 shares during the period. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Trading Up 4.4%

Shares of VERA opened at $42.04 on Thursday. The stock’s 50-day moving average price is $44.17 and its 200 day moving average price is $36.59. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $2.94 billion, a price-to-earnings ratio of -9.02 and a beta of 1.17. Vera Therapeutics, Inc. has a 12-month low of $18.53 and a 12-month high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05). During the same period in the prior year, the company posted ($0.72) earnings per share. As a group, research analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Insiders Place Their Bets

In related news, SVP Joseph R. Young sold 3,117 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $130,851.66. Following the completion of the transaction, the senior vice president directly owned 64,722 shares of the company’s stock, valued at $2,717,029.56. This trade represents a 4.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Sean Grant sold 4,949 shares of Vera Therapeutics stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $207,759.02. Following the sale, the chief financial officer owned 114,181 shares in the company, valued at $4,793,318.38. This represents a 4.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 33,490 shares of company stock valued at $1,405,910 in the last ninety days. 16.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms have issued reports on VERA. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vera Therapeutics in a report on Wednesday, November 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Wednesday, January 21st. Wedbush raised their price objective on shares of Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. JPMorgan Chase & Co. dropped their target price on shares of Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating on the stock in a research report on Friday, December 19th. Finally, TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a research note on Friday, December 5th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $81.45.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.